logo
NIH Lab Studying Deadly Pathogens Goes Offline Over Safety Issues. Is The Public At Risk?

NIH Lab Studying Deadly Pathogens Goes Offline Over Safety Issues. Is The Public At Risk?

Forbes04-05-2025
On April 29, 2025, the National Institute of Allergy and Infectious Diseases within the NIH put the brakes on research at its high containment lab (known as the Integrated Research Facility) at Fort Detrick, Maryland for a safety stand-down. The lab studies high consequence pathogens, such as Ebola virus and SARS-CoV-2. In a report from WIRED magazine, Bradley Moss, communication director for NIH's office of research services noted 'This decision follows identification and documentation of personnel issues involving contract staff that compromised the facility's safety culture, prompting this research pause.' The IRF's director, Dr. Connie Schmaljohn, an experienced scientist and expert on hantaviruses, was also placed on administrative leave.
No further information on the cause of the safety stand-down has been reported by the NIH; however, Fox News subsequently cited an anonymous source, who stated the cause was a 'lover's spat' between facility researchers, where one individual poked holes in another's protective equipment. 'That individual has since been fired, the official indicated.' The NIH public affairs office did not respond to a query for more information.
High consequence pathogens are 'serious and deadly agents that pose a substantial threat to domestic and global security.' Many are difficult to treat and frequently do not have a preventive vaccine. Consequently, they require specialized containment facilities to study them safely, because they are known to infect laboratorians. Some additional examples include Marburg and Lassa viruses and anthrax bacteria. These are some of the deadliest infectious pathogens on the planet, with death rates that can range from approximately 25 to 90%.
Laboratories that work with human or animal samples are categorized at different 'biosafety levels,' from BSL-1 to BSL-4, with each increase in level corresponding to increasingly dangerous pathogens and concomitant increases in required safety measures. Most hospital microbiology labs work at the BSL-2 level, where deadly organisms can be worked on, such as staphylococcus, streptococcus, or even HIV, but those disease can be handled safely by working under a microbiology safety cabinet (or 'hood') with HEPA filtration, wearing gloves and a lab coat and washing your hands when you leave the lab. The biggest risk to the laboratorians would be through a splash or penetration of the skin with a sharp instrument or needle.
At the BSL-3 level, we cross into a level where 'containment' measures are needed to protect the laboratorians. Pathogens at this level are known to infect through the air and therefore require specialized air handling and personal protective equipment, such as a respirator and gowns as well as decontamination measures upon exiting the lab. Organisms worked on at the BSL-3 level, although potentially deadly, such as plague or tularemia, usually have a specific vaccine or treatment. When we move into BSL-4, we are at maximum containment. At BSL-4, we separate the person from the pathogen by either a fully encapsulated 'space' suit or by working with the organism inside a glove box. Pathogens at this level are usually highly deadly and generally have limited or no vaccines or treatments. Viruses like Ebola, Lassa and Marburg are handled under BSL-4 precautions.
There are many reasons to study these pathogens. Some are considered possible biological weapons threats. Others cause disease in endemic regions around the world, particularly in less-developed regions, such as Africa and South America. These pathogens are deadly and can cause outbreaks, so there has been a concerted effort in the military, at the NIH and academic institutions to 1) understand the ecology of where they exist in nature, 2) determine how they spread and cause disease and 3) develop countermeasures, including ways to diagnose, treat and prevent them.
Whether the public is at risk largely depends on what the problem is. I've written previously that there are four basic ways a pathogen can 'escape' a lab: through the air, human exposure, hitching a ride on an animal or inanimate object and through deliberate release. The most likely is through human exposure from a lab accident, where a laboratorian becomes infected in the lab with something contagious and once they become ill, they can spread it to others. In this situation, the idea that a laboratorian would intentionally compromise a colleague's protective suit, thus putting them at potential risk of infection with a deadly agent is unconscionable and incredibly serious. Having said that, unless the individual whose protective suit was breached became infected, there is no risk to the public from a pathogen.
In my own personal experience working in a containment laboratory and managing laboratory safety stand-downs, these can be mandated after a specific safety breach has been identified, a general attitude or 'culture' of the institution has been lax regarding safety procedures or even in response to a specific political issue or new safety mandate. Usually, the first thing that happens is an assessment of what the problem is and if anyone is at risk. If there are specific issues identified, either with safety protocols or how the workers are following them, then re-training of the individuals or the entire institute is undertaken. If there are mechanical problems with the facility, such as with the air handling systems, decontamination machinery, such as autoclaves or other methods to decontaminate instruments or other equipment, then those need to be fixed. Once any urgent issues are handled, it is in the best interest of the institute to provide more information on what led to the stand-down. Absent that, it is difficult to make a true assessment of public risk and also to reduce speculation as to the actual cause.
A stand-down can cause significant disruption to ongoing experiments, especially if they include work with animals that have received a vaccine or that have been infected with a specific pathogen. The longer a stand-down lasts, the more damaging the disruption can be. Therefore, the key is to get to the root of the problem, fix it, restore the public trust and resume the important work as soon as feasible.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

How Trump Threw Out the Pandemic Playbook
How Trump Threw Out the Pandemic Playbook

Atlantic

time14 hours ago

  • Atlantic

How Trump Threw Out the Pandemic Playbook

As of last month, there is no one left in the White House whose sole job is to keep the nation safe from biological threats. The leader of the National Security Council's biosecurity directorate recently resigned. His staff had been pushed out, and his unit is now defunct. The Office of Pandemic Preparedness and Response Policy, established by Congress in 2022, has dwindled from a staff of about 20 under President Joe Biden to a staff of zero. The Trump administration has said that it's just reorganizing the bureaucracy and is prepared to handle biothreats. But our experience suggests otherwise. Without a leader from the NSC embedded in the White House and ready to coordinate other agencies, more people—including Americans—will get sick and die. We have spent years helping lead the U.S. government's efforts to contain the deadliest biological threats. One of us, Beth Cameron, helped found the NSC's biosecurity office, in 2016—created as a response to a deadly Ebola outbreak in West Africa that had begun a couple of years earlier. Ebola is a gruesome, highly contagious disease that causes its victims' organs, blood vessels, and immune cells to fail. The average lethality rate is about 50 percent. That outbreak killed more than 11,000 people across West Africa and cost the U.S. government billions of dollars to help contain. Despite our government's best efforts, 11 cases ultimately reached the U.S., and two were fatal. President Donald Trump terminated the NSC's biosecurity office during his first term, but Biden reestablished it—and just in time. In early February 2021, an ominous email came to the White House from federal health officials: reports of Ebola outbreaks in Guinea and the Democratic Republic of the Congo. The cases were close to the borders of Uganda and Rwanda, major travel hubs for the region. The White House was already managing the coronavirus pandemic and resulting economic crisis. But leaving Guinea and Congo to handle the Ebola outbreaks on their own was risky. So we activated a system developed through hard-learned lessons from past deadly outbreaks, designed to help contain them at their sources and to prepare for the worst at home. We sent public-health professionals to advise the affected countries. We took inventory of vaccines and other supplies so we would be ready to deploy them. We relied on a painstaking system of testing, vaccinations, and predeparture screenings in Congo and Guinea. We ensured that anyone who had been to an affected country and was seeking to come to the U.S. was funneled to one of a handful of American airports. The CDC and the Department of Homeland Security activated a program for tracing and contacting passengers after their arrival. One of us, Jon Finer—the principal deputy national security adviser at the time—led a team of senior health and national-security officials from across the government; it met every day to coordinate all of the moving parts, and to keep the president and other senior officials informed. It worked. The disease was entirely contained within the two source countries—no cases reached the U.S.—and 18 people died, a number that could have been exponentially higher. To strengthen our responses to future pandemics, lawmakers soon established the position of a U.S. coordinator for global health security; one of us, Stephanie Psaki, was the first person to hold that job. They also created the Office of Pandemic Preparedness and Response Policy in the White House. The Trump administration, tasked with upholding the law, is supposed to be staffing these offices. Not only has it failed to do that, but in just six months, it also has dismantled many of the early-warning-and-response systems that were built over decades. In Trump's second term, his team has fired thousands of public-health experts at the CDC, the FDA, and other agencies. It has canceled investments in safeguards against pandemic influenza, undermined confidence in vaccines, and cut funding for potential future outbreaks. It killed USAID and is scaling down the CDC's global role, canceling many of the programs that maintained ties to countries where disease outbreaks occur. It has withdrawn the U.S. from the World Health Organization. And it has created confusion about who in the U.S. government is in charge of the system for tracking deadly biothreats, whether naturally occurring, accidental, or deliberate. Put another way: The second Trump administration inherited a playbook, and then pushed out the people who knew how to run the plays. The United States is dealing with many biological threats at home and abroad, such as the bird flu and measles—with the latter, America is already facing the worst outbreak in decades. Scientists estimate about a 50–50 chance of another pandemic as severe as the coronavirus occurring in the next 25 years. The probability is even higher for smaller-scale threats, such as periodic Ebola outbreaks. Deadly biothreats are more and more likely to emerge for a range of reasons, including increased interaction between humans and animals, labs without sufficient biosecurity systems, easier public access to the information and technology needed to create or manipulate a bioagent, and continued concerns about the development of biological weapons by nefarious actors. The risk of death and economic disruption is only growing. America rebuilt the system of disease detection and response after the first Trump administration damaged it. That will be harder to do this time around. Far more officials have left the government. Will they be willing to come back, given the degree to which their work has been disparaged and their job security eviscerated? Stopping deadly diseases from reaching the United States is challenging at the best of times. Absent trusting relationships and, truth be told, a fair amount of pressure, affected countries aren't always forthcoming with information. (We dealt with one case that required resorting to threats to withhold U.S. support if the other government didn't share more data about an emerging outbreak.) Health imperatives can collide with political ones, such as when a country has to consider restricting travel. Questions can arise about how much of a vaccine or treatment should be shared with other countries, and how much should be kept at home (if a vaccine or treatment exists at all). But these are all reasonable policy debates that assume the system is basically functioning. In a worst-case scenario, we might not even know about a disease until it has started spreading in a major city with an international airport. With no warning, we will have less ability to stop the disease at its source, and less power, if it reaches our shores, to save American lives. The odds of us facing that scenario have now gone way up. This would be a terrible tragedy, and all the more so because it would be self-inflicted.

Mark Cuban says the US has got to keep investing in research if it wants to have a chance of beating China at AI
Mark Cuban says the US has got to keep investing in research if it wants to have a chance of beating China at AI

Business Insider

time20 hours ago

  • Business Insider

Mark Cuban says the US has got to keep investing in research if it wants to have a chance of beating China at AI

"Shark Tank" star Mark Cuban says the US can beat China at AI if it continues "investing in research of all kinds as a country." "The IP we create domestically is what the frontier models can buy or invest in to define their differentiation and advance forward," Cuban wrote on X in response to a post by David Sacks, the White House's AI and crypto czar, on the state of the AI race. When asked about his X post, Cuban told Business Insider that American research is "important, not just because of the outcome of the research itself, but its value to American frontier AI models" like ChatGPT and Gemini. Cuban said that any unique intellectual property produced can be "licensed to the models, for a fee, to be included in their training." This would not only offset research costs but also make the models more valuable, he added. "The quality and depth of the research we do in this country can help us stay ahead of China and other countries in the AI race," Cuban told Business Insider. "We need our Ph.D.s, our scientists, our experts, to stay here and contribute to society, and their IP to make American AI models the global leaders," he added. Since taking office in January, President Donald Trump's administration has been culling research grants for universities and research institutions like the National Institutes of Health (NIH). Please help BI improve our Business, Tech, and Innovation coverage by sharing a bit about your role — it will help us tailor content that matters most to people like you. What is your job title? (1 of 2) Entry level position Project manager Management Senior management Executive management Student Self-employed Retired Other Continue By providing this information, you agree that Business Insider may use this data to improve your site experience and for targeted advertising. By continuing you agree that you accept the Terms of Service and Privacy Policy . Researchers and scientists told Business Insider's Ayelet Sheffey in April that the cuts could stifle innovation and result in brain drain. "It absolutely endangers the United States' position as the global leader in medical research. And for that, we will pay," Peter Lurie, a recipient of an NIH grant terminated in March, told Sheffey. Staying ahead in the AI race has been a primary focus for the Trump administration, which unveiled its " AI Action Plan" last month. The 28-page plan calls for a light-touch approach to AI regulation compared to Trump's predecessor, President Joe Biden. In January, Chinese AI startup DeepSeek shocked the world with its high-performing but relatively cheap AI models. Trump said he viewed DeepSeek's accomplishment "as a positive, as an asset" for America. "The release of DeepSeek, AI from a Chinese company, should be a wake-up call for our industries that we need to be laser-focused on competing to win," Trump told GOP lawmakers in January.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store